[go: up one dir, main page]

AR062784A1 - Tratmiento de los vertigos con acetil -l- leucina - Google Patents

Tratmiento de los vertigos con acetil -l- leucina

Info

Publication number
AR062784A1
AR062784A1 ARP070104058A ARP070104058A AR062784A1 AR 062784 A1 AR062784 A1 AR 062784A1 AR P070104058 A ARP070104058 A AR P070104058A AR P070104058 A ARP070104058 A AR P070104058A AR 062784 A1 AR062784 A1 AR 062784A1
Authority
AR
Argentina
Prior art keywords
treatment
vertiges
leucina
acetil
leucine
Prior art date
Application number
ARP070104058A
Other languages
English (en)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AR062784A1 publication Critical patent/AR062784A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de la acetil-L-leucina y de sus sales farmacéuticamente aceptables para la preparacion de un medicamento destinado al tratamiento de los vértigos y de los trastornos del equilibrio de todo origen. Ventajosamente, la acetil-L-leucina es una mezcla a 100%.
ARP070104058A 2006-09-13 2007-09-13 Tratmiento de los vertigos con acetil -l- leucina AR062784A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0607992A FR2905600B1 (fr) 2006-09-13 2006-09-13 Traitement des vertiges par l'acetyl-l-leucine.

Publications (1)

Publication Number Publication Date
AR062784A1 true AR062784A1 (es) 2008-12-03

Family

ID=37709503

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104058A AR062784A1 (es) 2006-09-13 2007-09-13 Tratmiento de los vertigos con acetil -l- leucina

Country Status (12)

Country Link
US (1) US20090318555A1 (es)
EP (1) EP2068860A2 (es)
JP (1) JP2010503658A (es)
AR (1) AR062784A1 (es)
AU (1) AU2007297181B2 (es)
CA (1) CA2663206A1 (es)
FR (2) FR2905600B1 (es)
MX (1) MX2009002725A (es)
NZ (1) NZ576150A (es)
TW (1) TW200817030A (es)
WO (1) WO2008032222A2 (es)
ZA (1) ZA200901452B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
IL310508A (en) * 2016-04-19 2024-03-01 Intrabio Ltd Acetyl-leucine or its acceptable pharmacy salt for improved mobility and cognitive function
SI3359146T1 (sl) * 2016-08-11 2019-05-31 Intrabio Ltd Farmacevtski sestavki in uporabe, usmerjene na motnje lisosomalnega skladiščenja
CN109789114A (zh) * 2016-08-11 2019-05-21 内在生物技术有限公司 神经退行性疾病的治疗剂
GB201709459D0 (en) * 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
WO2019079536A1 (en) * 2017-10-18 2019-04-25 Intrabio Ltd THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS
KR20210135272A (ko) * 2019-03-02 2021-11-12 인트라바이오 리미티드 질환을 치료하기 위한 류신, 아세틸 류신, 및 관련된 유사체

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2941924A (en) * 1956-03-30 1960-06-21 Rhone Poulenc Sa Monoethanolamine salt of alpha-(acetylamino)-isocaproic acid
GB798680A (en) * 1956-03-30 1958-07-23 Rhone Poulenc Sa Improvements in or relating to the preparation of pharmaceutical compositions

Also Published As

Publication number Publication date
EP2068860A2 (en) 2009-06-17
TW200817030A (en) 2008-04-16
NZ576150A (en) 2011-11-25
WO2008032222A2 (en) 2008-03-20
MX2009002725A (es) 2009-03-25
FR2943537B1 (fr) 2011-05-13
FR2905600A1 (fr) 2008-03-14
FR2943537A1 (fr) 2010-10-01
CA2663206A1 (en) 2008-03-20
WO2008032222A3 (en) 2008-05-02
AU2007297181B2 (en) 2013-10-17
FR2905600B1 (fr) 2010-01-15
AU2007297181A1 (en) 2008-03-20
JP2010503658A (ja) 2010-02-04
ZA200901452B (en) 2010-04-28
US20090318555A1 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CR11857A (es) Compuestos pirazolicos 436
NI201000041A (es) Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma.
UY32203A (es) Amino pirimidinas y su uso en terapia
ECSP099663A (es) Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y métodos para utilizar la misma
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
AR062875A1 (es) Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
UY27740A1 (es) Nuevos compuestos
CR8858A (es) Derivados de sulfamato y sulfamida para el tratamiento de epilepsia y trastornos relacionados
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
GT200600258A (es) Derivados de n-(piridin-2-il)-sulfonamida
AR062784A1 (es) Tratmiento de los vertigos con acetil -l- leucina
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
UY29899A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
AR058163A1 (es) Medicamentos exhaltadores del deseo sexual que comprenden derivados de benzimidazolona
UY29609A1 (es) Derivados de benzamidina y usos relacionados de los mismos
MX2020007271A (es) Sales y cristales novedosos.
MX383650B (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
HN2004000109A (es) Nueva difenilazetidinona con propiedades fisiologicas mejoradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
HN2003000183A (es) Difenilazetidinonas sustituidas en anillo procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
MX383292B (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal